NCT00801177 is a Phase 1 clinical trial of IMC-11F8 in Solid Tumors, sponsored by Eli Lilly and Company.

Who is sponsoring NCT00801177?

NCT00801177 is sponsored by Eli Lilly and Company.

What drugs are being tested in NCT00801177?

Interventions in NCT00801177: IMC-11F8, IMC-11F8, IMC-11F8, IMC-11F8 I.V., IMC-11F8, IMC-11F8, IMC-11F8, IMC-11F8, IMC-11F8, IMC-11F8, IMC-11F8, IMC-11F8.

What condition does NCT00801177 study?

NCT00801177 studies Solid Tumors.

Is NCT00801177 still recruiting?

NCT00801177 is currently completed. Last updated 11 October 2010.

Last reviewed 2010-10-11 · How we verify

NCT00801177

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase I Study of the Fully Human Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody IMC-11F8 in Patients With Solid Tumors Who Have Failed Standard Therapy

Completed Phase 1 Last updated 11 October 2010

What this trial tests

Phase 1 trial testing IMC-11F8 in Solid Tumors in 60 participants. Completed in 1 February 2007.

Timeline

1 November 2004

Primary endpoint
1 February 2007

1 February 2007

Quick facts

Lead sponsor	Eli Lilly and Company
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Enrollment	60
Start date	1 November 2004
Primary completion	1 February 2007
Estimated completion	1 February 2007
Sites	2 locations across Netherlands

Drugs / interventions tested

IMC-11F8 — full drug profile →
IMC-11F8 — full drug profile →
IMC-11F8 — full drug profile →
IMC-11F8 I.V. — full drug profile →
IMC-11F8 — full drug profile →
IMC-11F8 — full drug profile →
IMC-11F8 — full drug profile →
IMC-11F8 — full drug profile →
IMC-11F8 — full drug profile →
IMC-11F8 — full drug profile →
IMC-11F8 — full drug profile →
IMC-11F8 — full drug profile →

Conditions studied

Solid Tumors — all drugs for Solid Tumors →

Sponsor

Eli Lilly and Company — full company profile →

Who can join

18 and older, any sex, with Solid Tumors. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Number of Participants with Adverse Events
Time frame: Approximately 24 Months
Maximum Tolerated Dose of IMC-11F8
Time frame: Approximately 24 Months

Sponsor's own description

The purpose of this study is to determine if IMC-11F8 is safe for patients, and also to determine the best dose of IMC-11F8 to give to patients.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Antibody phage display libraries: contributions to oncology.
Dantas-Barbosa C, De Macedo Brigido M, Maranhao AQ. · · 2012 · cited 27× · PMID 22754305 · DOI 10.3390/ijms13055420
EGFR Monoclonal Antibodies in the Treatment of Squamous Cell Carcinoma of the Head and Neck: A View beyond Cetuximab.
Kono SA, Haigentz M, Yom SS, Saba N. · · 2012 · cited 4× · PMID 23056941 · DOI 10.1155/2012/901320

Verify or expand the search:

Other recruiting trials for Solid Tumors

Currently open trials in the same condition.

NCT07529002 — Clinical Application of 89Zr-s-C1 PET/CT Imaging in Solid Tumors · recruiting
NCT07416123 — A Study of GEN1106 in Participants With Solid Tumors · Phase 1 · recruiting
NCT07522073 — A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancre · Phase 3 · recruiting
NCT07395258 — A Study to Test Different Doses of BI 3923948 Alone and in Combination With an Anti-PD-1 Antibody in People With Differe · Phase 1 · recruiting
NCT07505069 — Exploring the Clinical Value of RT01-89Zr PET Imaging in Solid Tumors · EARLY_PHASE1 · recruiting

Other Eli Lilly and Company trials

Trials by the same sponsor.

NCT07533006 — A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss) · Phase 2 · not yet recruiting
NCT07533019 — A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo · Phase 2 · not yet recruiting
NCT07247357 — A Study of LY4064809 in Healthy Adult Chinese Participants · Phase 1 · completed
NCT07124013 — A Study of Olomorasib (LY3537982) in Healthy Japanese Participants · Phase 1 · completed
NCT07030127 — A Study of LY3985863 in Healthy Participants · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00801177 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Eli Lilly and Company
Last refreshed: 11 October 2010

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00801177.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing